Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX)

Immatics N.V. (NASDAQ: IMTX ) is developing a cell therapy called Anzu-cel (anzutresgene autoleucel, IMA203) for melanoma and other potential cancers that could bring in hundreds of millions or more annually. The company has already produced some data with Anzu-celScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment a ...